03rd week of 2015 patent applcation highlights part 54 |
Patent application number | Title | Published |
20150018344 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R | 2015-01-15 |
20150018345 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS - The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C | 2015-01-15 |
20150018346 | COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH AGING AND DEGENERATIVE DISORDERS - The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder. | 2015-01-15 |
20150018347 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of chemokine receptor activity of formula I | 2015-01-15 |
20150018348 | Lactam Kinase Inhibitors - Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof. | 2015-01-15 |
20150018349 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS - In one aspect, the invention relates to substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the BTK kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the BTK kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2015-01-15 |
20150018350 | N-CONTAINING HETEROCYCLIC COMPOUNDS - The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. | 2015-01-15 |
20150018351 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 2015-01-15 |
20150018352 | SULFAMIDE SODIUM CHANNEL INHIBITORS - The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. | 2015-01-15 |
20150018353 | 2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS - Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 2015-01-15 |
20150018355 | COMPOUNDS AND METHODS FOR TREATING LEUKEMIA - Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms. | 2015-01-15 |
20150018356 | FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS - Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof. | 2015-01-15 |
20150018357 | CRYSTAL FORM OF (6S)-5-METHYLTETRAHYDROFOLATE SALT AND METHOD FOR PREPARING SAME - Disclosed are a crystal form of (6S)-5-methyltetrahydrofolate salt and a method for preparing the same. The crystal form is: Form C of the crystal form of (6S)-5-methyltetrahydrofolate calcium salt, where the X-ray diffraction pattern has diffraction peaks at the 2θ angles of 6.3±0.2 and 19.2±0.2; or the crystal form of (6S)-5-methyltetrahydrofolate strontium salt, where the X-ray diffraction pattern has diffraction peaks at the 2θ angles of 6.5±0.2 and 22.0±0.2. The crystal form of (6S)-5-methyltetrahydrofolate salt of the present invention has the advantages of excellent physicochemical properties, good stability, high purity, good reproducibility, and being more suitable for production on an industrial scale. | 2015-01-15 |
20150018358 | COMPOSITIONS AND METHODS FOR TREATING PURPURA - Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α | 2015-01-15 |
20150018359 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE - Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): | 2015-01-15 |
20150018360 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS - The present invention provides, inter alia, compositions containing enantiomerically pure (R)(+)-amisulpride or enantiomerically pure (R)(+)-sulpiride, optionally with dopamine receptor modulators. The present invention also provides compositions containing racemic (RS)-amisulpride or (RS)-sulpiride in combination with dopamine receptor modulators. Methods for preventing, treating, or ameliorating the effects of a metabolic disorder or key element thereof, for modulating blood glucose levels, and for preventing, treating, or ameliorating the effects of diabetes in a subject are also provided. Additionally, the present invention provides methods for counter-acting the dopamine antagonist activity of (S)-amisulpride in racemic (RS)-amisulpride, or the dopamine antagonist activity of (S)-sulpiride in racemic (RS)-sulpiride, administered to a subject to prevent, treat, or ameliorate the effects of a metabolic disorder. | 2015-01-15 |
20150018361 | ANTI-TUMOR ACTIVITY OF REDUCED FOLATES LIKE METHYLENE-TETRAHYDROFOLATE - The present invention relates to methylene-tetrahydrofolate for use in the treatment of cancer, based on its intrinsic antitumor activity. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma. | 2015-01-15 |
20150018362 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES - The invention described herein relates to methods for treating mitochondrial diseases. In particular, the invention relates to methods for treating mitochondrial diseases by administering therapeutically effective amounts of one or more tetracyclic pyrazinoindoles, and/or pharmaceutically acceptable salts thereof. | 2015-01-15 |
20150018363 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS - The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula | 2015-01-15 |
20150018364 | CONTROL OF HYPOXIA-INDUCIBLE GENE EXPRESSION WITH OLIGOOXOPIPERAZINE NONPEPTIDIC HELIX MIMETICS - The present invention relates to oligooxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF-1α. Also disclosed are pharmaceutical compositions containing these oligooxopiperazines and methods of using these oligooxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF-1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation). | 2015-01-15 |
20150018365 | Method of Treatment of Anxiety Disorder Comorbid with Depression Disorder - The present invention relates to a method for treating comorbid anxiety disorders and depression disorders, as well as for preventing depression disorders in individuals affected by anxiety disorders, by administering a therapeutically effective amount of the compound of general formula (I): | 2015-01-15 |
20150018366 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA | 2015-01-15 |
20150018367 | AURORA AND FLT3 KINASES MODULATORS - The invention provides a compound having the formula (1): | 2015-01-15 |
20150018368 | PROCESS FOR PREPARING BENZISOTHIAZOL-3-YL-PIPERAZIN-1-YL-METHYL-CYCLO HEXYLMETHANISOINDOL-1,3-DIONE AND ITS INTERMEDIATES - The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexyl-methan-isoindol-1,3-dione and intermediates thereof. | 2015-01-15 |
20150018369 | Compositions and Methods for Treating Malignant Astrocytomas - The disclosure provides methods of treating glioblastoma, methods of screening for compounds that treat glioblastoma, and pharmaceutical compositions useful in the treatment of glioblastoma. | 2015-01-15 |
20150018370 | Process for the preparation of form III of Vilazodone hydrochloride - The invention relates to a new solvate, Vilazodone hydrochloride monoethanol monohydrate solvate, and to a process for the preparation of polymorphic form III of Vilazodone hydrochloride via the Vilazodone hydrochloride monoethanol monohydrate solvate. | 2015-01-15 |
20150018371 | POSITIVE ALLOSTERIC MODULATORS FOR MELANOCORTIN RECEPTORS - Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator. | 2015-01-15 |
20150018373 | HETEROCYCLIC COMPOUND - Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): | 2015-01-15 |
20150018374 | FUNGICIDAL PYRAZOLE MIXTURES - Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, | 2015-01-15 |
20150018375 | COMPOSITIONS, METHOD, AND KITS FOR TREATING PULMONARY CONDITIONS - Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and/or a leucine metabolite, and resveratrol. | 2015-01-15 |
20150018376 | PYRIMIDIN-4-YL)OXY)-1H-INDOLE-1-CARBOXAMIDE DERIVATIVES AND USE THEREOF - This invention relates to certain metabolites of N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide In particular, the present invention relates to pharmaceutical compositions comprising these metabolites, as well as processes for their preparation and their use in the treatment of diseases. | 2015-01-15 |
20150018377 | IMIDAZOLIDINEDIONE DERIVATIVES - The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy. | 2015-01-15 |
20150018378 | FADS REGULATION - The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects. | 2015-01-15 |
20150018379 | Intranasal Pharmaceutical Dosage Forms Comprising Naloxone - The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≧0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≦250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof. | 2015-01-15 |
20150018380 | Methods of Screening for Activation Deaminase Inhibitors Through Nuclear Import Inhibitors - The present invention provides methods for obtaining specific and non-toxic inhibitors of AID nuclear import. The methods comprise a primary screen and a counter screen to identify a pool of AID specific nuclear import inhibitors that do not have off-target of toxic effects. AID specific nuclear import inhibitors identified by the screens of the invention prevent nuclear entry, limit the access of AID to genomic DNA, and inhibit AID mutagenic activity. Preparations, including pharmaceutical preparations, comprising specific nuclear import inhibitors, used for example, to inhibit cancer progression, are also encompassed in the invention. | 2015-01-15 |
20150018381 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 2015-01-15 |
20150018382 | Use of Rupatadine in the Manufacture of Pharmaceutical Composition for Treating Chronic Obstructive Pulmonary Disease - Disclosed is the use of rupatadine in the manufacture of pharmaceutical composition for preventing or treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease. The new medicament, i.e. rupatadine, for treating chronic obstructive pulmonary disease is obvious in therapeutic effects, and low in toxic and side effects, and safe in use in the aspects of treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease. | 2015-01-15 |
20150018383 | BIOMARKERS OF RENAL DISORDERS - The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof. | 2015-01-15 |
20150018384 | TREATMENT FOR HIGH CHOLESTEROL - The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (LDL-C) and/or very low density Opoproiein cholesterol (VLDL-C) in subjects In need thereof by administering a compound that inhibits HIF hydroxylase activity. The method is useful, for reducing LDL cholesterol levels and total cholesterol levels even In subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia. | 2015-01-15 |
20150018385 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS - The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors. | 2015-01-15 |
20150018386 | AMORPHOUS FORM OF APIXABAN, PROCESS OF PREPARATION AND COMPOSITIONS THEREOF - The present invention discloses an amorphous form of apixaban, process of preparation and compositions thereof. | 2015-01-15 |
20150018387 | HIGH CONCENTRATION LOCAL ANESTHETIC FORMULATIONS - A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours. | 2015-01-15 |
20150018388 | Treatment of Amyotrophic Lateral Sclerosis - The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds. | 2015-01-15 |
20150018389 | METHOD FOR TREATING PARKINSONS DISEASE AND OTHER NEUROLOGICAL DISEASES - A method for treating a central nervous system or peripheral nervous system dopaminergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a dopaminergic deficit state and for a time sufficient to achieve a suitable blood level to treat said dopaminergic deficit state. | 2015-01-15 |
20150018390 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING A LOCAL ANESTHETIC - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days. | 2015-01-15 |
20150018391 | ANIMAL TREATMENTS - Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal. | 2015-01-15 |
20150018392 | Liquid concentrate formulation containing a pyripyropene insecticide I - The present invention relates to a liquid concentrate formulation comprising a pyripyropene pesticide of the formula I as defined below and an alkoxylated aliphatic alcohol as an adjuvant. Moreover, the invention relates to the use of the formulations for the treatment of plants and seed and to corresponding methods. | 2015-01-15 |
20150018393 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS - The present invention provides compositions and methods for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST. | 2015-01-15 |
20150018394 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. | 2015-01-15 |
20150018395 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule. | 2015-01-15 |
20150018396 | PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA AGONIST - The present disclosure is related generally to a method for prevention and/or treatment of infections, e.g., respiratory infections, in a subject before or after the onset of a disease state associated with the infection. | 2015-01-15 |
20150018397 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO INCREASED EOSINOPHILS - Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole. | 2015-01-15 |
20150018398 | METHODS OF USING ESTROGEN RECEPTOR-BETA LIGANDS AS RADIATION MITIGATORS - Disclosed herein are methods useful for treating radiation damage in a subject. | 2015-01-15 |
20150018399 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 2015-01-15 |
20150018400 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I | 2015-01-15 |
20150018401 | NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1): | 2015-01-15 |
20150018402 | PESTICIDAL DISPERSIBLE CONCENTRATE FORMULATIONS - The present invention relates to non-aqueous pesticidal dispersible concentrate formulations comprising from about 2 to about 10% of at least one pesticidal agent, from about 15 to about 25% of hexylene glycol, from about 65 to about 75% of propylene glycol, a hydrophobic silica, and a surfactant, wherein the weight percentages are based on the total weight of the formulation. Formulations of the present invention have superior storage stability but are non-phytotoxic to seeds when used as a seed treatment. The present invention also relates to ready-to-use products made from the concentrated formulations of the present invention. Further, the present invention includes methods of using the pesticidal dispersible concentrate formulations and ready-to-use products to achieve superior plant protection and disease control. | 2015-01-15 |
20150018403 | FLUORENE-AMIDE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - A compound represented by the following formula: | 2015-01-15 |
20150018404 | DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS - The present application relates to double stranded nucleic acid compounds, compositions comprising same and methods of use thereof for the treatment of hearing loss in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA molecules which inhibit expression of a gene expressed selected from the group consisting of HES1, HES5, HEY1, HEY2, ID1, ID2, ID3, CDKN1B, and NOTCH1. | 2015-01-15 |
20150018405 | TREATMENT OF DISEASE BY MODULATION OF SIRT6 - An aspect of an embodiment of the invention relates to providing treatment of disease, in particular age-related disease, through increasing or decreasing the activity of SIRT6 protein. This may be accomplished through upregulation and downregulation of expression of SIRT6 in mammals. It has been found by the inventors that mice over-expressing SIRT6 have a longer lifespan in comparison to control mice, indicating that increasing SIRT6 expression can lengthen lifespan of mammals. Agents which modulate SIRT6 expression through, for example binding to 3′UTR region of human mRNA encoding SIRT6 or by blocking binding of agents to 3′UTR region of human mRNA encoding SIRT6, have been identified. | 2015-01-15 |
20150018406 | MODULATION OF BREAST CANCER GROWTH BY MODULATION OF XBP1 ACTIVITY - Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1a (HIF1a). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC. | 2015-01-15 |
20150018407 | METHOD FOR PROMOTING ANGIOGENESIS, VASCULARIZATION OR VESSEL REPAIR OR FOR INHIBITING TUMOR ANGIOGENESIS - The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92. | 2015-01-15 |
20150018408 | THERAPEUTIC ANTIBODIES AND USES THEREOF - Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases. | 2015-01-15 |
20150018409 | CHIMERIC POLYPEPTIDES AND THEIR USE - The presented invention concerns chimeric molecules that contain a preferential polypeptidic region, consisting of a specific affinity for the binding to specific DNA sequences, of a preferential polypeptidic region consisting of a DNA modifying activity, and this chimeric molecule is capable to cross biological membranes due to the presence of a region that contains delivery activity. The invention contains further the isolated polynucleotides that code for the chimeric molecules of the invention if they are as such entirely or partially of polypeptide nature. | 2015-01-15 |
20150018410 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS - The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds. | 2015-01-15 |
20150018411 | COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES - The present invention concerns substances which act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and which can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of this invention act as inhibitors of PPAR beta/delta receptors. | 2015-01-15 |
20150018412 | HIGH THROUGHPUT FABRICATION OF NANOPARTICLES - This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates). | 2015-01-15 |
20150018413 | Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same - The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof. | 2015-01-15 |
20150018414 | Promotion of Smoking Cessation - The present invention relates to a method for promoting cessation or reduction in the smoking and/or chewing of tobacco or nicotine-containing products in a subject in need thereof, comprising administering to the subject an effective amount of certain carbamate compounds. The invention further relates to a method for preventing relapse smoking and/or chewing of tobacco or nicotine-containing products in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 2015-01-15 |
20150018415 | THERAPEUTIC COMPOSITIONS - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 2015-01-15 |
20150018416 | Aqueous Ophthalmic Composition - The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol. | 2015-01-15 |
20150018417 | FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS - A class of enzymatically generated electrophilic fatty acid derivatives (EFADs), or their enzymatically generated metabolites. The EFAD's and their metabolites have beneficial effects human health. According to the inventors the inventive keto fatty acids or their enzymatically generated metabolites, can inhibit inflammation by giving rise to adaptive signaling molecules in vivo. | 2015-01-15 |
20150018418 | COMPOSITIONS AND METHODS FOR PROLONGING PREGNANCY - Provided are compositions and methods for use for prolonging pregnancy. The methods involve administering to an individual in need thereof an effective amount of a composition that contains a compound which is capable of specifically binding to an alpha2delta subunit of a voltage-gated calcium channel, such as gabapentin, pregabalin, and pharmaceutically acceptable salts and prodrugs thereof The composition is administered such that pregnancy is prolonged to by reducing, stopping, preventing and/or preventing recurrence of preterm labor during a human pregnancy. Also provides are articles of manufacture that have packaging containing one or a combination of compounds that are capable of specifically binding an alpha2delta subunit of a voltage-gated calcium channel. The compound is provided in an amount sufficient for alleviating and/or preventing preterm labor in a pregnant human female. The packaging comprises printed material, the printed material providing an indication that the pharmaceutical composition is for use in the alleviating or preventing of preterm labor and/or for prolonging pregnancy. | 2015-01-15 |
20150018419 | TRANEXAMIC ACID FORMULATIONS - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 2015-01-15 |
20150018420 | METHOD OF CONTROLLING THE RELEASE OF AN ACTIVE INGREDIENT FROM A DOSAGE FORM - A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of
| 2015-01-15 |
20150018421 | Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 2015-01-15 |
20150018422 | AROMATIC RING COMPOUND - Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): | 2015-01-15 |
20150018423 | Injectable Osteogenic Formula and Method of Using Same - Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix. | 2015-01-15 |
20150018424 | PROCESS FOR THE PREPARATION OF VORINOSTAT - The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient vorinostat. In particular it relates to a process for preparing vorinostat substantially free from impurities. | 2015-01-15 |
20150018425 | TITRATION PACKAGE FOR NERAMEXANE AND ITS USE IN THE TREATMENT OF AN INNER EAR DISORDER - The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus. | 2015-01-15 |
20150018426 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 2015-01-15 |
20150018427 | COMPOUNDS FOR TREATING PARVOVIRUS INFECTION - The present invention relates to compounds for use in a method for the treatment or prevention of parvovirus infections in humans and warm-blooded animals, including feline panleukopenia virus (FPV) infections in felids, canine parvovirus type 2 (CPV-2) infections in canines, minute virus of mice (MVM) infections in mice and B19 parvovirus infections in humans. | 2015-01-15 |
20150018428 | LUTEIN/ZEAXANTHIN FOR GLARE PROTECTION - The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin. | 2015-01-15 |
20150018429 | AZEOTROPE-LIKE COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE - This invention relates to azeotrope-like compositions, methods and systems having utility in numerous applications, and in particular, uses for azeotrope-like compositions comprising effective amounts of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: | 2015-01-15 |
20150018430 | HUMIDITY ACTIVATED FORMULATION FOR VOLATILE COMPOUNDS - This invention is related to controlled release formulations of volatile antimicrobial compounds against pathogens affecting meats, plants, or plant parts or dairy products. Provided are delivery systems in the form of coatings or films, where controlled release of their volatile components in vapor form is triggered by high relative humidity. The volatile component may include, for example volatile antimicrobial liquids including low molecular weight alcohols and/or aldehydes, 1-methylcyclopropene, and/or other volatile fungicides. | 2015-01-15 |
20150018431 | Lubricious Coating Compositions - In one aspect, the present disclosure pertains to lubricous coating compositions that comprise (a) a higher molecular weight polyvinylpyrrolidone, (b) a lower molecular weight polyvinylpyrrolidone, and (c) a polyfunctional unsaturated crosslinking agent. In some embodiments, such lubricous coating compositions are present in crosslinked form on the surface of a medical article. In some embodiments, the lubricous coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently crosslinked, thereby forming a lubricious coating on the substrate. In another aspect, the present disclosure is directed to methods for forming various medical articles. | 2015-01-15 |
20150018432 | Compositions and Methods Using Rebaudioside X to Provide Sweetness Enhancement - Sweetened compositions comprising at least one sweetener and rebaudioside X are provided herein. Rebaudioside X is present in the sweetened compositions in a concentration at or below the sweetness recognition threshold, while the at least one sweetener is present in a concentration above its sweetness recognition threshold. Rebaudioside X acts to enhance the sweetness of the sweetened compositions, e.g. beverages and concentrate compositions, thereby allowing for preparation of sweetened compositions with reduced calorie content. Methods of enhancing the sweetness of a sweetened composition with rebaudioside X are also provided herein. | 2015-01-15 |
20150018433 | FLUORINATED POLYMERIZABLE HYDROGELS FOR WOUND DRESSINGS AND METHODS OF MAKING SAME - Fluorinated hydrogels are used to dissolve oxygen or other oxygenated small molecules. The fluorinated hydrogels may release the dissolved oxygen or other oxygenated small molecules upon exposure to an environment of lower tension. The fluorinated hydrogels have a particular application in wound healing, where the fluorinated hydrogels may be used as a wound dressing. | 2015-01-15 |
20150018434 | COMPOSITION FOR ORAL DELIVERY OF VETERINARY DRUGS AND SUPPLEMENTS TO ANIMALS - Crushed pills containing medicines and/or supplements for animals are mixed with an edible paste formulated from all naturally occurring ingredients including specific starches that when mixed together bind the composition to the crushed pills. The mixture is designed to stick to animal fur as well as been very palatable to animal. The medicine is delivered to the animal by offering the paste from a spoon or finger or by smearing the paste on the animal, where it readily adheres to the fur and may be licked off. To encourage finicky animals such as cats to accept the composition from a spoon or finger, and to make it a pleasurable experience for them, the composition includes a desirable food such as real salmon or real meat. | 2015-01-15 |
20150018435 | POLYUNSATURATED FATTY ACID-CONTAINING OIL PRODUCT AND USES AND PRODUCTION THEREOF - The present invention includes a solid fat composition that includes an oil having saturated fat and a microbial oil having a long chain polyunsaturated fatty acid and an emulsifier. In particular, the solid fat composition can have high levels of long chain polyunsaturated fatty acid and low amounts of emulsifiers. In preferred embodiments, the polyunsaturated oil is an unwinterized microbial oil. The invention also relates to methods for making such compositions and food, nutritional, and pharmaceutical products comprising said compositions. The present invention also includes a microbial oil product prepared by extracting an oil-containing fraction comprising at least one LC-PUFA from a microbial biomass, and treating the fraction by a process of vacuum evaporation, wherein the oil product has not been subject to one or more of a solvent winterization step, a caustic refining process, a chill filtration process, or a bleaching process. | 2015-01-15 |
20150018437 | FISCHER-TROPSCH SYNTHESIS - A process ( | 2015-01-15 |
20150018438 | CATALYST ACTIVATION METHOD FOR FISCHER-TROPSCH SYNTHESIS - The present invention relates to: a catalyst activation method for Fischer-Tropsch synthesis; a catalyst regeneration method for Fischer-Tropsch synthesis; and a method for producing a liquid or solid hydrocarbon by using the Fischer-Tropsch synthesis reaction. The temperatures required for a metal carbide producing and activating reaction is markedly lower than existing catalyst activation temperatures, and the catalyst can be activated under conditions that are the same as Fischer-Tropsch synthesis reaction conditions, and thus there is no need for separate reduction equipment in the reactor, and a Fischer-Tropsch synthesis catalyst which has been used for a long time can be regenerated within the reactor without the catalyst being isolated or extracted from the reactor. | 2015-01-15 |
20150018439 | TREATING OF CATALYST CARRIER, FISCHER-TROPSCH CATALYSTS AND METHOD OF PREPARATION THEREOF - A method for the preparation of a modified catalyst support comprising: (a) treating a bare catalyst support material with an aqueous solution or dispersion of one or more titanium metal sources and one or more carboxylic acids; and (b) drying the treated support, and (c) optionally calcining the treated support. Also provided are catalyst support materials obtainable by the methods, and catalysts prepared from such supports. | 2015-01-15 |
20150018440 | TEMPERATURE-RESPONSIVE POLYMER PARTICLES IN PROTEIN SEPARATION APPLICATIONS - The present invention relates to a method for isolating proteins from a solution containing the proteins. The invention also relates to a method for the chromatographic separation of proteins. The present invention also relates to crosslinked hydroxylic polymer particles functionalized with temperature-responsive copolymer, and to methods of preparing such particles. | 2015-01-15 |
20150018441 | YELLOW THERMOCHROMIC DYES, INKS COMPOSITION AND LEVEL INDICATORS - A new leuco dye produces a yellow color while demonstrating also exceptional light and thermal stability under light. | 2015-01-15 |
20150018442 | METHOD FOR PREPARING MICROPOROUS POLYOLEFIN FILM BY THERMALLY-INDUCED PHASE SEPARATION METHOD - The present invention discloses a method for preparing a microporous polyolefin film comprising: a step of injecting a composition comprising polyolefin 30 to 60 wt % and a diluent mixture comprising a diluent, which can make liquid-liquid phase separation with the polyolefin thermodynamically 40 to 70 wt %, into an extruding machine, and melting and kneading thereof to prepare a single phase melt; and a step of extruding the melt while conducting liquid-liquid phase separation by passing through a section having the temperature below the liquid-liquid phase separation temperature and forming thereof in the form of a sheet, and a microporous polyolefin film prepared according to the method. | 2015-01-15 |
20150018443 | Cushioning Foams Containing Reflective Particulates With Visually Distinguishable Reflective Surfaces to Create a Unique Appearance - Methods and combinations for making and using reflective particulate foam comprising flexible cellular foam and a plurality of reflective particulates randomly and/or uniformly dispersed during the production of the reflective particulate foam. Reflective particulates have reflective surfaces which are visually distinguishable as individual reflective particulates without the use of magnification. Reflective particulate foam provides a novel and uniquely distinguishable appearance for use on, under, or within mattresses, pillows, bedding products, medical cushioning foams, outdoor bedding pads, pet beds, outdoor pillows, cushioned display cases, cushioned package containers, and other cushioning products. | 2015-01-15 |
20150018444 | COMPOSITION OF MATTER POLYOLS FOR POLYURETHANE APPLICATIONS - There are provided ester polyols prepared from the esterification of ozone acids and branched primary polyols. There are also provided ester polyol esters prepared from an ester polyol of the invention and further esterifying the ester polyol with at least one carboxylic acid to produce at least one ester polyol ester. There are also provided rigid or flexible foams prepared using the ester polyols and/or ester polyol esters of the invention. There is also provided a coating prepared from the ester polyols and/or ester polyols esters of the invention. | 2015-01-15 |
20150018445 | SEMI-CURED PRODUCT, CURED PRODUCT AND METHOD OF MANUFACTURING SAME, OPTICAL COMPONENT, CURABLE RESIN COMPOSITION - A curable resin composition comprising a (meth)acrylate monomer having an aromatic ring, a non-conjugated vinylidene group-containing compound represented by the general formula below, and a thermal or a photo-radical polymerization initiator makes it possible to produce a cured product with minimized occurrence of burring during molding and high product yield after molding. The cured product has good heat coloration resistance and low Abbe's number. R | 2015-01-15 |
20150018446 | ORGANOCATALYZED PHOTOREDOX MEDIATED POLYMERIZATION USING VISIBLE LIGHT - The present invention is directed to method of forming a polymer comprising exposing a mixture comprising an organic pre-polymer, an organic photoredox catalyst, and an organic initiator to a source of visible or near-infrared light under conditions and for a time sufficient to polymerize the organic pre-polymer, and polymers and articles derived therefrom. | 2015-01-15 |